Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inst. of Organic Chemistry and Biochemistry of the Czech Academy of Sciences ADRA2A compound 5: sourced facts only. name: "Notably, the 3-methyl-1,2,4-oxadiazole derivative 5 demonstrated highly potent ADRA2A antagonism (IC50 = 34 nM), exceptional off-target selectivity, and improved in vivo systemic exposure." [PMID:42854387]; target: "Notably, the 3-methyl-1,2,4-oxadiazole derivative 5 demonstrated highly potent ADRA2A antagonism (IC50 = 34 nM), exceptional off-target selectivity, and improved in vivo systemic exposure." [PMID:42854387]; developer: "Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 6, Prague, 160 00, Czech Republic." [PMID:42854387]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inst. of Organic Chemistry and Biochemistry of the Czech Academy of Sciences ADRA2A compound 5.